Quantum-Si (QSI) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
1 Dec, 2025Executive summary
The annual meeting will be held virtually on May 16, 2025, with voting and Q&A available online.
Stockholders will vote on electing ten directors, ratifying the auditor, and approving executive compensation.
The board recommends approval of all proposals and encourages prompt voting.
Proxy materials are primarily distributed electronically to conserve resources and reduce costs.
Voting matters and shareholder proposals
Proposals include electing ten directors, ratifying PricewaterhouseCoopers LLP as auditor, and a non-binding say-on-pay vote.
Each director is elected by a majority of votes cast; abstentions and broker non-votes have no effect.
Stockholders can submit proposals for the 2026 meeting by December 3, 2025, following SEC and bylaw requirements.
Board of directors and corporate governance
The board consists of ten members, with eight deemed independent under Nasdaq rules.
The company qualifies as a "controlled company" due to majority voting power held by a single individual but maintains a majority-independent board and independent committees.
Three standing committees: audit, compensation, and nominating/corporate governance, all with independent members.
Directors are elected annually; all attended at least 75% of meetings in 2024.
Corporate governance guidelines and an insider trading policy are in place.
Latest events from Quantum-Si
- 2026 emphasizes consumables growth and Proteus launch, with strong cash reserves and cost control.QSI
Q4 20253 Mar 2026 - Q2 2024 revenue rose 203% to $622,000, with a 57% margin and cash runway into 2026.QSI
Q2 20242 Feb 2026 - Rapid innovation and commercial expansion position the platform for strong growth in proteomics.QSI
Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase 20242 Feb 2026 - Automated protein sequencing platform drives adoption and innovation across research sectors.QSI
H.C. Wainwright 26th Annual Global Investment Conference21 Jan 2026 - Q3 revenue up 252.9% to $787,000, but full-year guidance was lowered amid longer sales cycles.QSI
Q3 202414 Jan 2026 - Proteus and Platinum Pro launch drive scalable, automated, and versatile proteomics workflows.QSI
Investor Day 202413 Jan 2026 - Q4 revenue up 52% sequentially, 183% YoY, $86M raised, and cash runway into 2027.QSI
Q4 202424 Dec 2025 - Up to $300M in securities may be offered, with $100M via at-the-market sales through Leerink Partners.QSI
Registration Filing16 Dec 2025 - Up to $300M in securities, including $100M at-the-market stock, to fund growth amid notable risks.QSI
Registration Filing16 Dec 2025